SMYD2 has been reported to be implicated in the development of cardiovascular disease, cancer, and autosomal dominant polycystic kidney disease (ADPKD) (Li et al., 2017; Tracy et al., 2018; Yi et al., 2019; Rueda-Robles et al., 2021). This evidence concerns the gene SMYD2 and autosomal dominant polycystic kidney disease.